Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ

Is Hikma Pharmaceuticals USA Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.

Does Hikma Pharmaceuticals USA Inc. hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Delaware Division of Professional Regulation also lists nonresident license AD-0010090 for Hikma Pharmaceuticals USA Inc., CHERRY HILL, NJ, status Closed, as of Nov 10, 2026.

Has Hikma Pharmaceuticals USA Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 2 FMD-145 letters (May 11, 2023 and Dec 16, 2024) for Hikma Pharmaceuticals USA Inc. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Hikma Pharmaceuticals USA Inc.
Location
Cherry Hill, NJ
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Dec 16, 2024
FDA Data Dashboard inspections
18 inspections: 7 VAI, 11 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 3 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Hikma Pharmaceuticals USA Inc., a 503B facility, with 3 dated actions.

Document
Dec 16, 2024FMD-145 letterFMD-145 Letter Issued 12/16/2024Not linked by FDA
Jun 12, 2024Form 483483 Issued 06/12/2024FDA copy (archived)
May 11, 2023FMD-145 letterFMD-145 Letter Issued 05/11/2023Not linked by FDA

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ (FEI number 2220525), matched to this page by exact name, city and state. It lists 18 inspections: 7 VAI, 11 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 13, 2026No Action Indicated (NAI)Drug Quality Assurance (Drugs)22205251304368
Jun 12, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)22205251237333
Nov 3, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)22205251222115
Jul 7, 2022No Action Indicated (NAI)Drug Quality Assurance (Drugs)22205251176451
Sep 10, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)22205251106822
Sep 14, 2018No Action Indicated (NAI)Drug Quality Assurance (Drugs)22205251067645
Apr 4, 2017No Action Indicated (NAI)Drug Quality Assurance (Drugs)22205251008043
May 21, 2015No Action Indicated (NAI)Drug Quality Assurance (Drugs)2220525927273
Sep 19, 2014No Action Indicated (NAI)Unapproved and Misbranded Drugs (Drugs)2220525896197
May 1, 2014No Action Indicated (NAI)Drug Quality Assurance (Drugs)2220525875193
Oct 22, 2013No Action Indicated (NAI)Drug Quality Assurance (Drugs)2220525854096
Jun 14, 2013Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)2220525837934
Mar 28, 2013No Action Indicated (NAI)Drug Quality Assurance (Drugs)2220525824820
Oct 24, 2012No Action Indicated (NAI)Drug Quality Assurance (Drugs)2220525804570
Apr 13, 2011Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)2220525719344
Oct 29, 2010Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)2220525695392
Mar 11, 2010No Action Indicated (NAI)Drug Quality Assurance (Drugs)2220525650967
Mar 10, 2009Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)2220525567761

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 29, 2024 to Jun 12, 2024: 3 observations

Firm on the cover
Hikma Pharmaceuticals USA Inc., 2 Esterbrook Ln, Cherry Hill, NJ 08003-4002
FEI number
2220525
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov); FDA also posts it as https://web.archive.org/web/20250506103522/https://www.fda.gov/media/180039/download

Observation 1

Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established and followed.

Specifically, your air visualization "smoke" studies, TestProtCHH15017 Protocol to Perform Smoke Profile in Room 115 and TestProtCHH15372 Protocol to Perform Smoke Study In Room 115for Machine Adjustments utilized by your firm to qualify your controlled environment revealed deficiencies.

For example:

A. In your protocol, TestProtCHH15017 operations under dynamic conditions were not included such as but not limited to, the changing of the settle plates (occur <Redacted B4>), refilling the <Redacted B4> with stoppers during filling operations and clearing a jam from the <Redacted B4> unit. These are operations that are part of your filling process as observed on 05/29/2024 of the filling of Fentanyl 10mcg/250ML lot <Redacted B4>. In addition, in the video titled Dynamic Machine Filling Station the "smoke" used to show the operation of the <Redacted B4> filler difficult to fully visualize. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, your firm's co-validated method transfer, ReportCHH15181 Method Transfer Report for SOPCHH15817 (TM D227} Determination of Fentanyl in Fentanyl Citrate in 0.9% Sodium Chloride Injection IV Bags omits established characteristics for conducting a method validation, such as but not limited to, Accuracy and instrument comparability. Your firm also provided Memo: FDA Discussion -Co-Validation of the Analytical Procedure for Fentanyl Citrate Injection Assay, dated June 6, 2024, to support your co-validation. TM D227 Determination of Fentanyl in Fentanyl Citrate in 0.9% Sodium Chloride Injection IV Bags was validated by your contracted testing laboratory on their premises and your co-validation was conducted in your Research and Development laboratory. The rationale to support not including characteristics of a method validation other than precision are not discussed in either document.

Observation 3

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, your firm did not follow the instructions outlined in your procedure, SOPCHH15028 Manufacturing Investigation Report (MIR) System. According to section 7.4.2.4 of SOPCHH15028, "when performing an investigation, if a review of previous lot data, stability and retain samples, customer complaints, Annual Product Reviews, and other identifiable data is performed, this documentation of reviews should be included in the investigation". However, the documentation of the following deviations QE-021941, QE-018568, and QE-007589 did not include the results and data of the additional samples taken to support the impact and risk assessment of the investigation.

additional samples taken to support the impact and risk assessment of the investigation.

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0010090Outsourcing Facility-DistributorHikma Pharmaceuticals USA Inc.CHERRY HILL, NJClosed

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming liraglutide under the labeler name “Hikma Pharmaceuticals USA Inc.”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: ANDA (1).

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

0143-9144
ANDA215503
LiraglutideliraglutideINJECTIONSUBCUTANEOUS6 mg/mLANDADec 24, 2024None givenDec 31, 2027Finished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.